NEW YORK (AP) -- Drugmaker Watson Pharmaceuticals Inc. said Friday it expects 2011 global revenue to climb in both its generic and branded segments, following a year in which net revenue grew 25 percent.
The Corona, Calif., company said it expects adjusted earnings per share between $3.85 and $4.15 on revenue of about $4.2 billion in 2011.
Analysts polled by FactSet expect, on average, earnings per share of $4.16 on about $4.15 billion in revenue.
Watson expects global generics revenue to grow to between $2.8 billion and $3 billion in 2011, up from an expected total of $2.35 billion last year. It anticipates global brand revenue of $470 million to $490 million in 2011, up from an expected total last year of $400 million.
The company's 2011 launches include a generic version of the Johnson & Johnson attention deficit hyperactivity disorder drug Concerta. Under an agreement that runs until the end of 2014, J&J will be the supplier for the "authorized" generic product and will receive a share of the net sales.
Shares of Watson Pharmaceuticals climbed 82 cents to $53.69 in afternoon trading.
The Corona, Calif., company said it expects adjusted earnings per share between $3.85 and $4.15 on revenue of about $4.2 billion in 2011.
Analysts polled by FactSet expect, on average, earnings per share of $4.16 on about $4.15 billion in revenue.
Watson expects global generics revenue to grow to between $2.8 billion and $3 billion in 2011, up from an expected total of $2.35 billion last year. It anticipates global brand revenue of $470 million to $490 million in 2011, up from an expected total last year of $400 million.
The company's 2011 launches include a generic version of the Johnson & Johnson attention deficit hyperactivity disorder drug Concerta. Under an agreement that runs until the end of 2014, J&J will be the supplier for the "authorized" generic product and will receive a share of the net sales.
Shares of Watson Pharmaceuticals climbed 82 cents to $53.69 in afternoon trading.
